Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Medical Devices & Mechanical Engineering
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
L&C Bio Co., Ltd. is currently navigating 2 pending office actions within the Medical Devices & Mechanical Engineering technology area. These actions are distributed across 2 distinct examiners and 2 distinct art units. This spread indicates that the company's patent filings are being reviewed by different technical groups within the USPTO, suggesting a range of medical device innovations that fall under different jurisdictional boundaries.
KIM, CRAIG SANG is identified as the busiest examiner, managing 1 pending office action. Given the total of 2 pending office actions, the workload is split equally among the 2 distinct examiners. The involvement of 2 distinct art units suggests that the applications may cover different aspects of medical devices that require specialized technical expertise. This decentralized prosecution model means that the company must tailor its arguments to the specific requirements of each examiner.
For the applicant, managing 2 pending office actions across 2 distinct examiners requires a diversified prosecution strategy. The lack of concentration in a single art unit means there is no central technical authority for these filings. With 1 pending office action per examiner, the company must address the specific concerns of two different individuals in two different administrative units. Success in these matters depends on effectively resolving the issues raised in both of the 2 pending office actions.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KIM, CRAIG SANG | 1 | 86.3% | +9.8% |
| IANNUZO, NATALIE NMN | 1 | 12.5% | +71.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17795930 | COMPOSITION COMPRISING CARTILAGE INGREDIENT FOR REGENERATION OF CARTILAGE AND PREPARATION METHOD THEREFOR | IANNUZO, NATALIE NMN | 22d overdue |
| 18553107 | COMPOSITION INJECTION DEVICE | KIM, CRAIG SANG | 11d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17795930 | COMPOSITION COMPRISING CARTILAGE INGREDIENT FOR REGENERATION OF CARTILAGE AND PREPARATION METHOD THEREFOR | IANNUZO, NATALIE NMN | 22d overdue |
| Art Unit | Apps |
|---|---|
| 3741 | 1 |
| 1653 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18553107 | COMPOSITION INJECTION DEVICE | KIM, CRAIG SANG | 3741 | §102§103§112 | Non-Final OA | 11d overdue | Pending | Sep 28, 2023 |
| 17795930 | COMPOSITION COMPRISING CARTILAGE INGREDIENT FOR REGENERATION OF CARTILAGE AND PREPARATION METHOD THEREFOR | IANNUZO, NATALIE NMN | 1653 | §103 | Non-Final OA | 22d overdue | Pending | Jul 28, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial